Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

PALO ALTO, Calif.: PALO ALTO, Calif., Aug. 5, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported its second quarter 2021 financial results and provided a business update. "Our rapidly...

Click to view original post